Assessment High-Risk Breast Cancer in Older Patients: A Comparative Analysis of PREDICT Scores and TAILORx Risk Categorization

Basit Öğe Kaydı
dc.WoS.categoriesOncologyen_US
dc.authorid0000-0003-0917-2098en_US
dc.contributor.authorÜnal, Çağlar
dc.contributor.authorÖzmen, Tolga
dc.contributor.authorDuymaz, Tomris
dc.date.accessioned2024-04-16T09:17:11Z
dc.date.available2024-04-16T09:17:11Z
dc.date.issued2023-10
dc.description.abstractObjective: This study aimed to evaluate the relationship between PREDICT tool overall survival (OS) scores and high-risk patients according to TAILORx risk categorization in elderly hormone reseptor (HR) positive human epidermal growth factor negative early breast-cancer patients. Materials and Methods: We conducted a retrospective study, extracting data from medical records of 64 patients diagnosed with breast cancer. A retrospective analysis was performed on all patients who had Oncotype Dx Recurrence Scores across five medical centers between 2017 and 2022. PREDICT scores were defined as calculated 10-year OS rates via PREDICT tool. Results: The median age of the patients was 67, with a range between 65-75 years. Low-risk patients had a slightly higher two PREDICT scores compared to high-risk patients (78% vs. 73%), (81% vs. 77%), which were statistically significant. The progesterone receptor (PR) level was significantly lower in the high-risk group (3.5% vs. 80%). A unit decrease in the PREDICT scores was associated with a 11% increase in the odds of being in the high-risk group. However, these effects weren't statistically significant in the multivariate analysis. A unit decrease in the PR level was significantly associated with increased odds (by 5% in the multivariate analysis) of being in the high-risk group. Conclusion: Our study underscores the importance of using a combination of tools, including the PREDICT tool, PR levels, and TAILORx risk categorization, for a comprehensive risk assessment in these patients, especially in the older population. Accurate risk assessment is crucial for tailoring the treatment and optimizing outcomes in this vulnerable population. Future studies are warranted to further validate these findings in larger cohorts and to explore additional biomarkers and genomic signatures that may aid in the risk assessment and management of breast cancer in older patients.en_US
dc.fullTextLevelFull Texten_US
dc.identifier.doi10.4274/ejbh.galenos.2023.2023-8-5en_US
dc.identifier.issn2587-0831
dc.identifier.pmid37795003en_US
dc.identifier.scopus2-s2.0-85174843943en_US
dc.identifier.urihttps://hdl.handle.net/11411/5259
dc.identifier.urihttps://doi.org/10.4274/ejbh.galenos.2023.2023-8-5
dc.identifier.wosWOS:001155115400010en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.issue4en_US
dc.language.isoenen_US
dc.nationalInternationalen_US
dc.numberofauthors10+en_US
dc.pages325-330en_US
dc.publisherGALENOS PUBL HOUSEen_US
dc.relation.ispartofEUROPEAN JOURNAL OF BREAST HEALTHen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast canceren_US
dc.subjectPREDICT toolen_US
dc.subjectoncotype DX recurrence scoreen_US
dc.subjectTAILORx risk categorizationen_US
dc.titleAssessment High-Risk Breast Cancer in Older Patients: A Comparative Analysis of PREDICT Scores and TAILORx Risk Categorizationen_US
dc.typeArticleen_US
dc.volume19en_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
2023WosDuymaz.pdf
Boyut:
357.3 KB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Faculty of Health Sciences
PubMed Indexed Publications
Scopus Indexed Publications
Web of Science Indexed Publications